Skip to main content
SpringerLink
Log in

Nierenbeteiligung bei monoklonalen Leichtkettenerkrankungen

Renal involvement in monoclonal light chain diseases

  • Leitthema
  • Published:
Der Nephrologe Aims and scope

Zusammenfassung

Erkrankungen, die mit der Bildung von monoklonalen Proteinen einhergehen, können die Nierenfunktion in unterschiedlicher Art und variablem Ausmaß beeinflussen. Dieser Artikel gibt einen Überblick über die Pathophysiologie, Epidemiologie und Diagnostik der häufigsten Formen (akute und chronische Myelomniere, AL-Amyloidose, monoklonale Immunglobulindeposition). Vor allem in der Therapie der „akuten Myelomniere“ wurden in den letzten Jahren auch neue therapeutische Optionen (Hämodialyse mit High-cut-off-Membranen) entwickelt, deren Effizienz wir mit älteren Strategien vergleichen.

Abstract

Diseases associated with monoclonal protein production can cause deterioration of kidney function in different ways and to varying degrees. This review provides an overview of the pathophysiology, epidemiology and diagnostic procedures of the most important kidney diseases (acute and chronic cast nephropathy, AL amyloidosis, monoclonal immunoglobulin deposition disease) associated with monoclonal proteins. Recently new approaches to treat cast nephropathy have been published (e.g. high cut-off membrane dialysis) and these will be dealt with in the light of other therapeutic options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Augustson BM, Begum G, Dunn JA et al (2005) Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002 – Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 23:9219–9226

    Article  PubMed  Google Scholar 

  2. Batuman V (2007) Proximal tubular injury in myeloma. Contrib Nephrol 153:87–104

    Article  PubMed  CAS  Google Scholar 

  3. Blade J, Fernandez-Llama P, Bosch F et al (1998) Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158:1889–1893

    Article  PubMed  CAS  Google Scholar 

  4. Chanan-Khan AA, Kaufman JL, Mehta J et al (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109:2604–2606

    Article  PubMed  CAS  Google Scholar 

  5. Clark WF, Stewart AK, Rock GA et al (2005) Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 143(11):777–784

    PubMed  Google Scholar 

  6. Devata S, Hari P, Markelova N et al (2011) Detection of amyloid in abdominal fat pad aspirates in early amyloidosis: role of electron microscopy and Congo red stained cell block sections. Cytojournal 8:11

    Article  PubMed  Google Scholar 

  7. Dispenzieri A, Kyle R, Merlini G et al (2009) International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:215–224

    Article  PubMed  CAS  Google Scholar 

  8. Eleutherakis-Papaiakovou V, Bamias A, Gika D et al (2007) Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 48:337–341

    Article  PubMed  CAS  Google Scholar 

  9. Ganeval D, Noel LH, Preud’homme JL et al (1984) Light-chain deposition disease: its relation with AL-type amyloidosis. Kidney Int 26:1–9

    Article  PubMed  CAS  Google Scholar 

  10. Heilman RL, Velosa JA, Holley KE et al (1992) Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 20:34–41

    PubMed  CAS  Google Scholar 

  11. Hutchison CA, Cockwell P, Reid S et al (2007) Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 18:886–895

    Article  PubMed  CAS  Google Scholar 

  12. Hutchison CA, Cook M, Heyne N et al (2008) European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 9:55

    Article  PubMed  Google Scholar 

  13. Hutchison CA, Harding S, Hewins P et al (2008) Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 3:1684–1690

    Article  PubMed  CAS  Google Scholar 

  14. Johnson WJ, Kyle RA, Pineda AA et al (1990) Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 150:863–869

    Article  PubMed  CAS  Google Scholar 

  15. Jones HB (1848) On the new substance occuring in the urine of a patient with mollities ossium. Philos Trans R Soc Lond 138:8

    Google Scholar 

  16. Katzmann JA, Clark RJ, Abraham RS et al (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48:1437–1444

    PubMed  CAS  Google Scholar 

  17. Knudsen LM, Hjorth M, Hippe E (2000) Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 65:175–181

    Article  PubMed  CAS  Google Scholar 

  18. Korngold L, Lipari R (1956) Multiple-myeloma proteins. I. Immunological studies. Cancer 9:183–192

    Article  PubMed  CAS  Google Scholar 

  19. Leung N, Gertz MA, Zeldenrust SR et al (2008) Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 73:1282–1288

    Article  PubMed  CAS  Google Scholar 

  20. Leung N, Lager DJ, Gertz MA et al (2004) Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 43:147–153

    Article  PubMed  Google Scholar 

  21. Lin J, Markowitz GS, Valeri AM et al (2001) Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 12:1482–1492

    PubMed  CAS  Google Scholar 

  22. Ludwig H, Adam Z, Hajek R et al (2010) Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 28:4635–4641

    Article  PubMed  CAS  Google Scholar 

  23. MacLennan IC, Kelly K, Crockson RA et al (1988) Results of the MRC myelomatosis trials for patients entered since 1980. Hematol Oncol 6:145–158

    Article  PubMed  CAS  Google Scholar 

  24. Neuwirt H, Rudnicki M, Schramek H, Mayer G (2011) Monoclonal light chains and the kidney. Nephrol Rev 3:13–22

    Google Scholar 

  25. San-Miguel JF, Richardson PG, Sonneveld P et al (2008) Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 22:842–849

    Article  PubMed  CAS  Google Scholar 

  26. Sanders PW, Herrera GA, Kirk KA et al (1991) Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest 64:527–537

    PubMed  CAS  Google Scholar 

  27. Skinner M, Sanchorawala V, Seldin DC et al (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140:85–93

    PubMed  CAS  Google Scholar 

  28. Winearls CG (1995) Acute myeloma kidney. Kidney Int 48:1347–1361

    Article  PubMed  CAS  Google Scholar 

  29. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G (1988) Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 33:1175–1180

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seinen Koautoren an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Universitätsklinik für Innere Medizin IV (Nephrologie und Hypertensiologie), Medizinische Universität Innsbruck, Anichstr. 35, 6020, Innsbruck, Österreich

    H. Neuwirt & G. Mayer

Authors
  1. H. Neuwirt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Neuwirt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neuwirt, H., Mayer, G. Nierenbeteiligung bei monoklonalen Leichtkettenerkrankungen. Nephrologe 8, 150–155 (2013). https://doi.org/10.1007/s11560-012-0717-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-012-0717-9

Schlüsselwörter

Keywords

Search

Navigation